# A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

> **NCT01682187** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 66 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** LY2157299
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT01682187
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-15
- **Primary completion:** 2012-05-22
- **Final completion:** 2024-09-30
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682187, "A Dose-Escalation Study in Participants With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01682187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*